Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 5021537, 13 pages
http://dx.doi.org/10.1155/2016/5021537
Research Article

Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance

1Department of Pediatrics and Department of Emergency, West China Second University Hospital, Sichuan University, Chengdu 610041, China
2Department of Immunology, School of Basic Medical Sciences, Chengdu Medical College, Chengdu 610083, China

Received 7 September 2016; Accepted 20 November 2016

Academic Editor: Alessandra Santos

Copyright © 2016 Yan Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Torres-Aguilar, M. Blank, L. J. Jara, and Y. Shoenfeld, “Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity,” Autoimmunity Reviews, vol. 10, no. 1, pp. 8–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Reis E Sousa, “Dendritic cells in a mature age,” Nature Reviews Immunology, vol. 6, no. 6, pp. 476–483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Rutella, S. Danese, and G. Leone, “Tolerogenic dendritic cells: cytokine modulation comes of age,” Blood, vol. 108, no. 5, pp. 1435–1440, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. R. M. Steinman, D. Hawiger, and M. C. Nussenzweig, “Tolerogenic dendritic cells,” Annual Review of Immunology, vol. 21, pp. 685–711, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Price, “Experimental arthritis: therapeutic effects of tolerogenic dendritic cells,” Nature Reviews Rheumatology, vol. 6, no. 12, p. 674, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Llanos, J. P. Mackern-Oberti, F. Vega, S. H. Jacobelli, and A. M. Kalergis, “Tolerogenic dendritic cells as a therapy for treating lupus,” Clinical Immunology, vol. 148, no. 2, pp. 237–245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. N. Stoop, R. A. Harry, A. Von Delwig, J. D. Isaacs, J. H. Robinson, and C. M. U. Hilkens, “Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses,” Arthritis and Rheumatology, vol. 62, no. 12, pp. 3656–3665, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Raϊch-Regué, L. Grau-López, M. Naranjo-Gómez et al., “Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients,” European Journal of Immunology, vol. 42, no. 3, pp. 771–782, 2012. View at Publisher · View at Google Scholar
  9. Y. Ren, Y. Yang, J. Yang, R. Xie, and H. Fan, “Tolerogenic dendritic cells modified by tacrolimus suppress CD4+ T-cell proliferation and inhibit collagen-induced arthritis in mice,” International Immunopharmacology, vol. 21, no. 1, pp. 247–254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Adorini, N. Giarratana, and G. Penna, “Pharmacological induction of tolerogenic dendritic cells and regulatory T cells,” Seminars in Immunology, vol. 16, no. 2, pp. 127–134, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. E. B. Lee, R. Fleischmann, S. Hall et al., “Tofacitinib versus methotrexate in rheumatoid arthritis,” The New England Journal of Medicine, vol. 370, no. 25, pp. 2377–2386, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. H. Coombs, B. J. Bloom, F. C. Breedveld et al., “Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 413–416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. F. van Vollenhoven, “Small molecular compounds in development for rheumatoid arthritis,” Current Opinion in Rheumatology, vol. 25, no. 3, pp. 391–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. H. M. Baldwin, T. Ito-Ihara, J. D. Isaacs, and C. M. U. Hilkens, “Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 1200–1207, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Rivas-Caicedo, G. Soldevila, T. I. Fortoul, A. Castell-Rodríguez, L. Flores-Romo, and E. A. García-Zepeda, “Jak3 is involved in dendritic cell maturation and CCR7-dependent migration,” PLoS ONE, vol. 4, no. 9, article e7066, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Kubo, K. Yamaoka, M. Kondo et al., “The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells,” Annals of the Rheumatic Diseases, vol. 73, no. 12, pp. 2192–2198, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Maeshima, K. Yamaoka, S. Kubo et al., “The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells,” Arthritis and Rheumatism, vol. 64, no. 6, pp. 1790–1798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. S. Farias, G. S. Spagnol, P. Bordeaux-Rego et al., “Vitamin D3 induces IDO+ tolerogenic DCs and enhances treg, reducing the severity of EAE,” CNS Neuroscience and Therapeutics, vol. 19, no. 4, pp. 269–277, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Comabella, X. Montalban, C. Münz, and J. D. Lünemann, “Targeting dendritic cells to treat multiple sclerosis,” Nature Reviews Neurology, vol. 6, no. 9, pp. 499–507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Inaba, M. Inaba, N. Romani et al., “Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor,” Journal of Experimental Medicine, vol. 176, no. 6, pp. 1693–1702, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. I. M. Stromnes and J. M. Goverman, “Active induction of experimental allergic encephalomyelitis,” Nature Protocols, vol. 1, no. 4, pp. 1810–1819, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Zandman-Goddard, S. S. Pierangeli, S. Gertel, and M. Blank, “Tolerogenic dendritic cells specific for β2-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome,” Journal of Autoimmunity, vol. 54, pp. 72–80, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. W. Way and B. Popko, “Harnessing the integrated stress response for the treatment of multiple sclerosis,” The Lancet Neurology, vol. 15, no. 4, pp. 434–443, 2016. View at Publisher · View at Google Scholar
  24. J. Goverman, “Autoimmune T cell responses in the central nervous system,” Nature Reviews Immunology, vol. 9, no. 6, pp. 393–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. Z.-X. Xie, H.-L. Zhang, X.-J. Wu, J. Zhu, D.-H. Ma, and T. Jin, “Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis,” Mediators of Inflammation, vol. 2015, Article ID 513295, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Anandasabapathy, G. D. Victora, M. Meredith et al., “Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain,” Journal of Experimental Medicine, vol. 208, no. 18, pp. 1695–1705, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. G. B. Ferreira, C. A. Gysemans, J. Demengeot et al., “1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD Mice,” The Journal of Immunology, vol. 192, no. 9, pp. 4210–4220, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Segura, M. Touzot, A. Bohineust et al., “Human inflammatory dendritic cells induce Th17 cell differentiation,” Immunity, vol. 38, no. 2, pp. 336–348, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Tanaka, C. E. Demeure, M. Rubio, G. Delespesse, and M. Sarfati, “Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio,” The Journal of Experimental Medicine, vol. 192, no. 3, pp. 405–412, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Rothhammer, S. Heink, F. Petermann et al., “Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE,” The Journal of Experimental Medicine, vol. 208, no. 12, pp. 2465–2476, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Sonobe, H. Li, S. Jin et al., “Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells,” Journal of Immunology, vol. 188, no. 6, pp. 2602–2611, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Fransson, E. Piras, J. Burman et al., “CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery,” Journal of Neuroinflammation, vol. 9, article 112, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Yoshida, A. Kimura, T. Fukaya et al., “Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation,” Biochemical and Biophysical Research Communications, vol. 418, no. 2, pp. 234–240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Ghoreschi, M. I. Jesson, X. Li et al., “Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550),” Journal of Immunology, vol. 186, no. 7, pp. 4234–4243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Mansilla, R. Contreras-Cardone, J. Navarro-Barriuso et al., “Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients,” Journal of Neuroinflammation, vol. 13, no. 1, article 113, 2016. View at Publisher · View at Google Scholar
  36. C. C. Gross, H. Jonuleit, and H. Wiendl, “Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis,” European Journal of Immunology, vol. 42, no. 3, pp. 569–572, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. J. B. Rothbard, X. Zhao, O. Sharpe et al., “Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis,” The Journal of Immunology, vol. 186, no. 7, pp. 4263–4268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Ayoglu, N. Mitsios, I. Kockum et al., “Anoctamin 2 identified as an autoimmune target in multiple sclerosis,” Proceedings of the National Academy of Sciences of the United States, vol. 113, no. 8, pp. 2188–2193, 2016. View at Publisher · View at Google Scholar
  39. A. Brickshawana, S. R. Hinson, M. F. Romero et al., “Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: A comparative study,” The Lancet Neurology, vol. 13, no. 8, pp. 795–806, 2014. View at Publisher · View at Google Scholar · View at Scopus